SCHEMBL6205088

SCHEMBL6205088

C=Cc1cc(OC(F)(F)F)ccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 5/20 0.41
ALDH1A1 P00352 1/20 0.39
FFAR4 Q5NUL3 6/20 0.38
SCN5A Q14524 3/20 0.38
CYP2C9 P11712 2/20 0.38
FFAR1 O14842 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
CYP3A4 P08684 2/20 0.37
GMNN O75496 1/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
GAA P10253 1/20 0.37
PKM P14618 1/20 0.37
ALOX15 P16050 1/20 0.37
NFKB1 P19838 1/20 0.37
SLC6A2 P23975 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6201722 0.82 FFAR4 (0.41) GPR3FFAR4SCN5ACYP2C9FFAR1
SCHEMBL16959124 0.82 FFAR4 (0.41) GPR3FFAR4SCN5ACYP2C9FFAR1
SCHEMBL16953635 0.80 GPR3 (0.42) GPR3ALDH1A1SCN5ACYP2C9NPC1
SCHEMBL16955162 0.80 GPR3 (0.42) GPR3FFAR4SCN5ACYP2C9FFAR1
SCHEMBL16950613 0.79 GPR3 (0.41) GPR3ALDH1A1SCN5ACYP2C9NPC1
SCHEMBL16958727 0.79 GPR3 (0.45) GPR3FFAR4SCN5ACYP2C9NPC1
SCHEMBL29894167 0.77 GPR3 (0.48) GPR3FFAR4SCN5ACYP2C9FFAR1
SCHEMBL8065084 0.77 GPR3 (0.48) GPR3FFAR4SCN5ACYP2C9FFAR1
SCHEMBL2366206 0.76 PDE2A (0.44) GPR3SCN5ACYP2C9NPC1RAB9A
SCHEMBL16959108 0.76 CYP1A1 (0.44) GPR3CYP1A2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900645-A1 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION Bayer CropScience AG (DE) 2015-08-05 EP disclosed
EP-1551836-A1 AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2005-07-13 EP disclosed
WO-2004031190-A1 AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2004-04-15 WO disclosed
US-6555552-B2 Psychological disorders; analgesics; antiinflammatory agents MERCK SHARP & DOHME LTD. (GB) 2003-04-29 US disclosed
US-20020147212-A1 Azabicyclic amine derivatives and their use as therapeutic agents MERCK SHARP & DOHME LTD. (GB) 2002-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147212-A1 Azabicyclic amine derivatives and their use as therapeutic agents CXCR1, CXCR6, CCR6 GPR3 268/4885ALDH1A1 1514/4885FFAR4 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.